GMI

Isorhamnetin exerts its neuroprotective effect by mediating the neuroinflammatory IL-6/TYK2 signaling pathway, suggesting its potential for treating AD.

n/a


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *